Sign inJoin waitlistJoin the waitlist

VB

Vassiliki Boussiotis

Professor, Department of Medicine · Beth Israel Deaconess Medical Center

Credentials: · · ·

History

Beth Israel Deaconess Medical Center
Present

Hematology and Medical Oncology
1983–1986
Internal Medicine
Brigham and Women's Hospital
1980–1983
University of Athens, Greece
National and Kapodistrian University of Athens School of Medicine
1976–1980

Research

PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Nature Immunology · 2001 · 2,369 citations
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Review · New England Journal of Medicine · 2016 · Sole author · 1,100 citations
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
Nature Communications · 2015 · Last of 12 authors · Corresponding · 1,027 citations

Lee Nadler
36 papers
Anthos Christofides
12 papers · 7 as a resident
Dimitrios Tzachanis
12 papers · 8 as a resident
Jerome Ritz
10 papers
Corey Cutler
9 papers
IP
Ioannis Politikos
9 papers · 4 as a fellow
Karen Ballen
9 papers
Joseph Antin
8 papers
Leonard Appleman
8 papers · 2 as a fellow
TK
Theodoros Karantanos
8 papers · 8 as a resident
NO
Natalia Tijaro Ovalle
7 papers · 5 as a resident
David Avigan
6 papers

Grants

Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy
National Cancer Institute · R35
Contact PI · $1.7M · Beth Israel Deaconess Medical Center
2025–2032
Dissecting Orchestrated Immune Responses to Glioblastoma Within the Native Tissue Microenvironment to Improve Treatment Outcomes
National Institute of Neurological Disorders and Stroke · R01
PI · $1.4M · Beth Israel Deaconess Medical Center
2025–2030
Understanding the Cellular and Functional Changes in the Immune Tumor Microenvironment of Glioblastoma During Progression and Treatments.
National Cancer Institute · R01
PI · $2.6M · Beth Israel Deaconess Medical Center
2023–2028
Detection of PD-1 Inhibitory Signaling and Its Molecular Relays in T Cells: Implications for Cancer Immunotherapy
National Cancer Institute · R01
Contact PI · $2.8M · Beth Israel Deaconess Medical Center
2023–2027